Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.71 USD
-0.77 (-2.61%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $28.72 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RARE 28.71 -0.77(-2.61%)
Will RARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Other News for RARE
Pocket Pivot appears for RARE after 1.66% move
20 Day Moving Average Resistance appears for RARE after 4.32% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
Is RARE ready to move lower? Fell Below 20 Day Moving Average shows up after dropping 2.95%
Non-ADX 1,2,3,4 Bullish appears for RARE after 0.19% move